Natera

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Natera reports robust Q4 results, eyes growth in genetic testing

Natera's Q4 2022 performance reflects strong growth in tests and revenues, particularly in oncology, setting the stage for future success.
The company's strategic milestones, new board appointment, and focus on clinical business growth highlight its resilience and market leadership.
While facing challenges in cost management and market competition, Natera has opportunities to leverage positive industry trends and policy changes for sustained growth.

Natera posts strong Q1 results, focuses on clinical differentiation

Natera's Q1 earnings call highlighted robust financials, strategic focus on clinical differentiation, and efforts to improve margins through ASP and COGS projects. Despite challenges with ASP and gross margins, the company remains optimistic about its trajectory and growth opportunities in women's health and organ health.

Natera reports stellar Q2 results, eyes growth amid regulatory changes

Natera delivered a strong Q2 performance with robust revenue growth, improved margins, and strategic advancements across oncology, women's health, and organ health segments.
The company showcased strengths in clinical utility, peer-reviewed publications, and litigation victories, while also addressing challenges like pricing pressures and regulatory changes.
Opportunities lie in expanding market reach through ACOG meetings, commercial coverage enhancements, and leveraging competitor exits for growth in carrier testing business.
Overall, Natera's revised guidance, financial outperformance, and focus on innovation position the company for continued success and market leadership in the genomics space.

Natera (NTRA) reports robust Q3 earnings, eyes market expansion

Natera (NTRA) delivered strong financial performance in Q3 2023, with raised revenue guidance and improved cash burn guidance.
The company's focus on achieving cash flow breakeven in 2024 while driving innovation and market engagement highlights a strategic growth trajectory.
While facing challenges such as pending lawsuits and regulatory uncertainties, Natera is well-positioned to capitalize on opportunities like market expansion and product innovation.

Natera reports robust earnings, eyes growth through strategic acquisitions

Natera's strong financial performance, strategic acquisitions, and focus on key developments position the company for continued growth.
While challenges like maintaining ASP trends and managing competition exist, opportunities in revenue growth, clinical studies, and guideline expansions offer potential upside.
Careful execution, volume growth, and momentum will be crucial for Natera's success in 2024, supported by confidence in their guidelines and innovative testing approaches.

Natera excels in Q1, eyes revenue growth and margin improvement

Natera's Q1 performance was outstanding, marked by revenue growth, margin expansion, and progress in key clinical areas.
While challenges like replicating exceptional performance and seasonal dips exist, the company is well-positioned for future growth.
Opportunities lie in improving margins, volume growth, and market penetration, supporting Natera's ambitious revenue targets.

Natera reports record-breaking Q3 earnings, poised for continued growth

Natera's Q3 2024 showcased exceptional financial performance, strong clinical advancements, and strategic debt management, positioning the company for sustained growth and innovation.
While facing challenges in community penetration and operational expenses, Natera's focus on innovation, customer service, and expanding clinical trials presents significant opportunities for future success.
With a clear focus on oncology patients, groundbreaking research, and upcoming data readouts, Natera remains poised for continued growth and leadership in the precision medicine space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

1-800-FLOWERS.COM

PHILADELPHIA--(BUSINESS WIRE)--Enclara Pharmacia, the nation's leading hospice-focused pharmacy services provider, announces the launch of a bidirectional medication interface with MatrixCare, a leader in out-of-hospital healthcare technology solutions. This integration between Enclara's E3 ProTM platform and MatrixCare's electronic health record (EHR) delivers real-time, two-way communication between systems, enabling hospice clinicians to save time and provide quality patient care through sec.

Enclara Pharmacia Announces Real-Time, Two-Way Medication Integration With MatrixCare's Electronic Health Record Platform

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera's Second Quarter 2024 Financial Results Date: Thursday, Aug. 8, 2024 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In:.

Natera to Report its Second Quarter 2024 Results on August 8, 2024

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncology highlighting the utility of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, for surveillance in Merkel cell carcinoma (MCC). The full study can be found here. MCC is an aggressive skin cancer with high mortality and a recurrence rate of 40% within 5 years.1 MRD testing using a viral.

New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell Carcinoma

Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductive genetics will be presented at the 28th International Conference on Prenatal Diagnosis and Therapy. Hosted by the International Society of Prenatal Diagnosis (ISPD), the conference will take place July 7-10, 2024, in Boston, MA. Below is the list of poster presentations that will be shared at the.

Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroesophageal cancer trial, DECIPHER, that will utilize the company's personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer. DECIPHER (Developing ctDNA Guided Adjuvant Therapy for Gastroesophageal Cancer).

Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera's ability to detect rejection in heart transplant patients. Traditionally, donor-derived cell-free DNA (dd-cfDNA) tests have reported rejection risk based only on the fraction of dd-cfDNA in the blood vs. the total cfDNA (dd-cfDNA %). This fraction can be confounded by.

Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 7:40 a.m. PT (10:40 a.m. ET). A live webcast may be accessed through the investor relations section of the Natera website at investor.natera.com. A replay of the event will be available shortly following the conference. About Natera Natera™ is a global lead.

Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its Prospera donor-derived cfDNA (dd-cfDNA) test at the American Transplant Congress (ATC) 2024 taking place June 1–5, 2024. Natera and its collaborators will present 18 abstracts highlighting new Prospera data across heart, lung, kidney, and multi-organ transplantation. This includes an oral presentation highlightin.

Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of Natera's management will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Thursday, May 30, 2024 at 8:40 a.m. PT (11:40 a.m. ET). A live webcast may be accessed through the investor relations section of the Natera website at investor.natera.com. A replay of the event will be available shortly following the conference. About Na.

Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024. The presentations feature data across a variety of indications, including breast cancer, colorectal cancer (CRC), lung cancer, melanoma, esophageal cancer, and urothelial cancer, with one or.

Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting

Natera stock rocketed to a three-year high Friday, buoyed by a "robust beat-and-raise" and its first-ever quarter of positive cash flow.

Why Natera Is 'A Stock To Focus On' Following Its Mighty Beat-And-Raise

Natera, Inc. (NASDAQ:NTRA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - President, Clinical Diagnostics Alex Aleshin - General Manager Oncology and Chief Medical Officer Conference Call Participants Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Catherine Schulte - Baird Matt Sykes - Goldman Sachs Operator Thank you for standing by. My name is Greg, and I will be your conference operator today.

Natera, Inc. (NTRA) Q1 2024 Earnings Call Transcript

The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. Recent Strategic and Financial Highlights Achieved positive cash flow of approximately $3.0 million1 in the first quarter of 2024. Generated total revenues of $367.7 million in the first quarter of 2024, compared to $241.8 million in the first quarter of 2023, an increase of 52.1%. Product revenues gre.

Natera Reports First Quarter 2024 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be found here. The study evaluated a total of 1,136 prospectively collected and banked plasma samples from 156 early-sta.

New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera's First Quarter 2024 Financial Results Date: Thursday, May 9, 2024 Time: 1:30 p.m. PT (4:30 p.m. ET) Live.

Natera to Report its First Quarter 2024 Results on May 9

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg). Natera's test can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient, including.

Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera's technology in the scientific literature. Landmark cutting-edge science and clinical trial data based on Natera's suite of products have been published in top journals, such as Science, Nature, Nature Medicine, and New England Journal of.

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection. The published manuscript can be found here. The ProActive study is the largest prospective dd-cfDNA study in kidney transplant recipients, with roughly 5,000 patients enrolled a.

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart donor-derived cfDNA (dd-cfDNA) test to detect rejection in adult and pediatric heart transplant recipients. These are the second and third peer-reviewed publications evaluating Natera's technology for use in heart transplantation. “We are encouraged by the resul.

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France. The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera's personalized and tumor-informed molecular residual disease (MRD) test. Sponsored by Genentech, a member of th.

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

Allogene Therapeutics Inc

Air Products and Chemicals

Sendas Distribuidora SA

American Express

BYD Company Limited

BYD Co Ltd

Cooper-Standard Holdings

Camden Property

Dollar General

Delek US Hlds

EPR Properties

Graco

Guardant Health Inc

SPDR Gold Trust

Intuitive Surgical

Kennedy-Wilson Holdings

MicroStrategy Incorporated

Nu Holdings

Omega Healthcare Investors

Portillo's

PayPal

Rolls-Royce Holdings PLC

There were 24 new analysts in March 2024. Gold, Bitcoin, a Bitcoin proxy pair trade, preferred shares, and a SOTP thesis are all covered.

Showcasing Seeking Alpha's March 2024 New Analysts

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical Trials in Oncology, which is part of the National Clinical Trials Network (NCTN) funded by the National Cancer Institute (NCI), part of National Institutes of Health, today announced the launch of Alliance A032103 (MODERN), a randomized, phase II/III, biomarker-integrated trial. Alliance A032103 (MODERN) will utilize Signatera™, Natera's personalized and tumor-inf.

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer

The global market size for personalized medicines is estimated to reach $1,233.23 billion by 2033, with North America experiencing significant growth in the oncology sector. Natera Inc., a diagnostic company, focuses on women's health, oncology, and organ health, with major revenue drivers including non-invasive prenatal tests and personalized molecular residual disease tests. Natera reported a 43% year-on-year increase in revenue in Q4 2023, with a goal to achieve cash flow break even by Q3 2024 or sooner.

News for Natera Stock (NTRA)